Amgen AMGN XGEVA — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amgen in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Amgen’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amgen's xgeva — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amgen's XGEVA — total revenues?
- Amgen (AMGN) reported XGEVA — total revenues of $411M in Q1 2026.
- How has Amgen's XGEVA — total revenues changed year-over-year?
- Amgen's XGEVA — total revenues decreased by 27.4% year-over-year, from $566M to $411M.
- What is the long-term trend for Amgen's XGEVA — total revenues?
- Over 4 years (2021 to 2025), Amgen's XGEVA — total revenues has grown at a 0.8% compound annual growth rate (CAGR), from $2.02B to $2.08B.
- What does XGEVA — total revenues mean?
- This metric represents the total gross sales generated by the XGEVA product line, a therapeutic agent used for the prevention of skeletal-related events in patients with bone metastases from solid tumors. It reflects the market demand, pricing power, and competitive positioning of this specific oncology asset within the company's broader portfolio. Monitoring this revenue stream is critical for assessing the lifecycle performance of mature biotechnology products and their contribution to overall segment growth.